Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-27T09:02:18.603Z Has data issue: false hasContentIssue false
  • English
  • Français

Oral Mycostatin as a possible alternative treatment for intractable Ménière's disease: preliminary cohort study

Published online by Cambridge University Press:  19 March 2014

A C Leong ,
D D Pothier  and
J A Rutka
A C Leong*
Affiliation:
Department of Otology and Neurotology, Toronto General Hospital, Canada
D D Pothier
Affiliation:
Department of Otology and Neurotology, Toronto General Hospital, Canada
J A Rutka
Affiliation:
Department of Otology and Neurotology, Toronto General Hospital, Canada
*
Address for correspondence: Dr A Leong, Department of Otology and Neurotology, Toronto General Hospital, University Health Network, Toronto, Ontario M5G 2C4, Canada E-mail: ackleong@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

The potential efficacy of antifungal agents (e.g. Mycostatin) in treating acute attacks of Ménière's disease was first suggested in 1983 but few data have been published. Oral Mycostatin has been used as second-line medical treatment for intractable Ménière's disease at our institution for many years.

Objective:

This preliminary cohort study investigated the role of oral Mycostatin in intractable Ménière's disease.

Methods:

A retrospective review of patients with intractable Ménière's disease who started oral Mycostatin treatment between 2010 and 2012 was conducted.

Results:

Of 256 patients presenting with vertiginous disorders, 26 had definite Ménière's disease and had not responded to standard first-line treatment. Following oral Mycostatin treatment, improvements were reported for vertigo (n = 8), aural fullness (n = 7), tinnitus (n = 3) and subjective hearing loss (n = 3). Half of those with symptom improvement persisted with oral Mycostatin for two years and continued to remain asymptomatic.

Conclusion:

The use of oral Mycostatin to alleviate symptoms of intractable Ménière's disease showed promising results in this case series. Mycostatin may offer a safe and useful alternative for the management of Ménière's disease for patients with chronic unremitting symptoms in whom first-line treatment options have failed.

Keywords

Antifungal AgentsMeniere DiseaseNystatin
Type
Short Communication
Information
The Journal of Laryngology & Otology , Volume 128 , Issue 4 , April 2014 , pp. 379 - 380
Copyright
Copyright © JLO (1984) Limited 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Nelson, RA. Successful treatment of immune inner ear symptoms with nystatin: preliminary findings. Presented at the 28th Annual Scientific Meeting of the American Neurotology Society, 17 April 1993, Los Angeles, California. In: http://www.mwilliamson.com/hearingloss.htm [13 February 2014]Google Scholar
2Wilson, WH. Antigenic excitation in Meniere's disease. Laryngoscope 1972;82:1726–35CrossRefGoogle ScholarPubMed
3McMillan, JJ. Fungus sensitivity as a cause of Meniere's disease? Arch Otolaryngol Head Neck Surg 2005;131:830Google Scholar
4Dimitrova, P, Danova, S, Ivanovska, N. Pro-inflammatory action of Candida albicans DNA in zymosan-induced arthritis. Inflamm Res 2012;61:649–56CrossRefGoogle ScholarPubMed
5Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere's disease. American Academy of Otolaryngology – Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:181–5CrossRefGoogle Scholar
6Torok, N. Old and new in Meniere disease. Laryngoscope 1977;87:1870–7Google Scholar
7Silverstein, H, Smouha, E, Jones, R. Natural history vs. surgery for Meniere's disease. Otolaryngol Head Neck Surg 1989;100:6–16CrossRefGoogle ScholarPubMed